Marcus and Feldman's Osteoporosis

5th Edition - October 8, 2020
Editors: David W. Dempster, Jane A. Cauley, Mary L. Bouxsein, Felicia Cosman
Language: English
Hardback ISBN:
9 7 8 - 0 - 1 2 - 8 1 3 0 7 3 - 5
eBook ISBN:
9 7 8 - 0 - 1 2 - 8 1 3 0 7 4 - 2

Marcus and Feldman's Osteoporosis, Fifth Edition, is the most comprehensive, authoritative reference on this disease. Led by a new editorial team, this fifth edition offers critic… Read more

Purchase options

LIMITED OFFER

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code is needed.

Institutional subscription on ScienceDirect

Request a sales quote

Marcus and Feldman's Osteoporosis, Fifth Edition, is the most comprehensive, authoritative reference on this disease. Led by a new editorial team, this fifth edition offers critical information on reproductive and hormonal risk factors, new therapeutics, ethnicity, nutrition, therapeutics, management and economics, comprising a tremendous wealth of knowledge in a single source not found elsewhere. Written by renowned experts in the field, this two-volume reference is a must-have for biomedical researchers, research clinicians, fellows, academic and medical libraries, and any company involved in osteoporosis drug research and development.

Volume 1.
Part I. Introduction

1. The Nature of Osteoporosis

2. The Bone Organ System: Form and Function
Part II. Developmental, Cellular and Molecular Biology of Bone

3. Development of the Skeleton

4. The Skeletal Stem Cell

5. Osteoclast Biology

6. Osteoblast Biology: Developmental Origin and Interactive Nature of Osteoblasts

7. Osteocytes

8. The Regulatory Role of Matrix Proteins in Mineralization of Bone
Part III. Skeletal Hormones and Regulatory Factors

9. Parathyroid Hormone and Parathyroid Hormone-Related Protein

10. Phosphatonins

11. Skeletal Growth Factors

12. WNT Signaling in Skeletal Homeostasis and Diseases
Part IV. Biomechanics and Mechanobiology

13. The Mechanical Behavior of Bone

14. Cellular and Molecular Mechanotransduction in Bone

15. Adaptation of Skeletal Structure to Mechanical Loading

16. Biomechanics of Hip and Vertebral Fractures
Part V. Epidemiology of Osteoporosis

17. Epidemiologic Methods in Studies of Osteoporosis

18. Genetics of Osteoporosis

19. Race, Ethnicity, and Osteoporosis

20. Geographic Variability in the Incidence of Hip and Vertebral Fractures

21. Nutrition and Osteoporosis

22. Physical Activity, Exercise and Skeletal Health

23. Reproductive and Hormonal Factors and the Risk for Osteoporosis

24. Clinical and Epidemiological Studies: Skeletal Changes across Menopause

25. Osteoporosis in Men: What is Similar and What is Different?

26. Falls as Risk Factors for Fracture

27. Impact of Physical Characteristics and Lifestyle Factors on Bone Density and Fractures

28. Imminent Fracture Risk and Disability Post Fracture

29. Economics of Osteopososis
Part VI. General Pathophysiology of Osteoporosis

30. Skeletal Heterogeneity and the Purposes of Bone Remodeling

31. On the Evolution and Contemporary Roles of Bone Remodeling

32. Estrogen Deficiency and the Pathogenesis of Osteoporosis

33. Cytokines and the Pathogenesis of Osteoporosis

34. Bone and Fat

35. Bone, Muscle, and Sarcopenia

36. Bone Mineral Acquisition in Utero and During Infancy and Childhood

37. Osteoporosis in Childhood and Adolescence

38. Osteoporosis in Premenopausal Women, Pregnancy, and Lactation

39. Bone and the Microbiome

Volume 2.
Part VII. Impact of Comorbidity and Medications on Skeletal Health

40. Immobilization Osteoporosis

41. Osteoporosis in Neurological Disorders: Parkinson’s Disease, Stroke, and Multiple Sclerosis--July 28, 2019

42. Effects on the Skeleton from Medications Used to Treat Non-skeletal Disorders

43. Osteoporosis associated with gastrointestinal disorders; celiac and inflammatory bowel diseases

44. Osteoporosis Associated with Eating Disorders

45. Glucocorticoid-Induced Osteoporosis and Cushing's Syndrome

46. Thyroid Hormone, Thyroid Medication, and the Skeleton

47. The Skeletal Actions of Parathyroid Hormone in Primary Hyperparathyroidism

48. Osteogenesis Imperfecta and Other Defects of Bone Development as Occasional Causes of Adult Osteoporosis

49. Human Immunodeficiency Virus and Osteoporosis

50. Diabetes, Diabetic Medications, and Risk of Fracture

51. Skeletal Health after Bariatric Surgery

52. Osteoporosis in Organ Transplant Patients

53. Osteoporosis Associated with Rheumatologic Disorders

54. Osteoporosis Associated with Chronic Kidney Disease

55. Relationship Between Periodontal Disease, Tooth Loss and Osteoporosis

56. Impact of Breast Cancer and its treatment on Bone Loss and Fracture Risk – Pathophysiology and Management

57. Management of Bone Health in Men with Prostate Cancer

58. Impact of MGUS and Myeloma on Skeletal Health

59. Renal Stone Disease, Hypercalciuria and Osteoporosis: Use of Thiazides and Alkali for Osteoporosis

60. Sleep Disorders and Osteoporosis
Part VIII. Diagnosis and Evaluation

61. Evaluation of the Osteoporosis Patient

62. Who Should be Screened for Osteoporosis?

63. Vertebral Fracture Identification

64. Noninvasive Imaging Techniques and Fracture Risk Assessment

65. Biochemical Markers of Bone Turnover in Osteoporosis

66. A Comparison of Fracture Risk Assessment Tools
Part IX. Patient Management

67. Orthopedic Aspects of Osteoporosis

68. Fall Prevention Interventions

69. Exercise and Other Physical Therapy Interventions in the Management of Osteoporosis

70. Calcium and Vitamin D in the Management of Osteoporosis

71. Nutrients Beyond Calcium and Vitamin D to Treat Osteoporosis

72. Condition Still Critical: Compliance and Persistence with Osteoporosis Medications
Part X. Pharmacotherapeutics

73. Estrogen and Estrogen Analogs for Prevention and Treatment of Osteoporosis

74. Bisphosphonates Pharmacology and Use in the Treatment of Osteoporosis

75. Denosumab for the Treatment of Osteoporosis

76. Teriparatide and Abaloparatide Treatment for Osteoporosis

77. Calcitonin in Osteoporosis

78. Androgens

79. Long-term Bisphosphonate Treatment: Continuation and Interruption

80. Romosozumab in the Treatment of Postmenopausal Osteoporosis

81. Lessons from Bone Histomorphometry on the Mechanisms of Action of Osteoporosis Drugs
Part XI. New Directions

82. Longterm Treatment Strategies and Goal Directed Therapy

David W. Dempster

David W. Dempster, PhD, is Professor of Clinical Pathology and Cell Biology at Columbia University in New York. He obtained his PhD from the University of Glasgow in Scotland and completed postdoctoral studies in Switzerland and France. Dr. Dempster is a Past President of the International Society of Bone Morphometry and a member of the Scientific Advisory Council of the National Osteoporosis Foundation. He is also a Fellow of the Royal Microscopical Society. Dr. Dempster’s iconic micrographs of osteoporotic bone have been widely reproduced in the scientific and popular press, including being displayed at the Smithsonian Institution in Washington, DC. Dr. Dempster is an Associate Editor of Osteoporosis International, and serves on the editorial boards of the Journal of Bone and Mineral Research, Bone and the Journal of Clinical Densitometry. His research studies have been continuously supported by the National Institutes of Health for the past 25 years. Dr. Dempster has published over 200 research papers on the pathophysiology and treatment of bone disese.

Affiliations and expertise

Professor of Clinical Pathology and Cell Biology, Columbia University School of Medicine; Director Emeritus, Regional Bone Center, Helen Hayes Hospital, New York, NY, USA

Jane A. Cauley

Dr. Cauley, DrPH, is a Distinguished Professor and Executive Vice Chair, Department of Epidemiology, Graduate School of Public Health (GSPH), University of Pittsburgh (Pennsylvania). Her primary research interest is the epidemiology of osteoporosis especially the large worldwide ethnic and geographic variability in fracture, osteoporosis screening and treatment, risk factors for fractures and the consequences of osteoporosis in both men and women. Her research has also focused on women's health and aging, falls, the interaction between endogenous and exogenous hormones, risk factors, and disease outcomes. She was principal investigator for several large cohort studies including the Study of Osteoporotic Fractures (SOF) and the Osteoporotic Fractures in Men (MrOS) study. She is a co-investigator for the Study of Women’s Health Across the Nation (SWAN) with particular emphases on skeletal health and physical function and body composition changes, novel measures of hip strength and the trabecular bone score across menopause. She initiated breast cancer follow-up in SOF and was the first to demonstrate an association between bone mineral density (BMD) and breast cancer, suggesting that BMD could be used as a cumulative measure of lifetime exposure to estrogen. Dr. Cauley has authored more than 800 papers for scientific journals and 28, book chapters. She co-edited a book entitled the Epidemiology of Aging, published in 2012.

Affiliations and expertise

Distinguished Professor of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, United States

Mary L. Bouxsein

Mary L. Bouxsein, PhD is Professor of Orthopedic Surgery at Harvard Medical School and Director of the Center for Advanced Orthopedic Studies at Beth Israel Deaconess Medical Center. Her group has focused on understanding the biomechanics of skeletal fragility, including age-related fractures and stress fractures due to novel physical activity. Her team aims to gain insight into the contribution of mechanical loading to fracture risk via advanced subject-specific musculoskeletal modeling. She has used non-invasive imaging technologies to characterize bone microstructure in animal models and in humans, and has show the contribution of bone microstructure to skeletal fragility in several clinical scenarios. In addition, her group has studied the impact of unloading and microgravity on the musculoskeletal system. Dr. Bouxsein is a Fellow of the American Society for Bone and Mineral Research, and has served on the Council of the ASBMR and the Board of the International Osteoporosis Foundation. She has received funding from the NIH, NASA and the Department of Defense. Dr. Bouxsein has published over 350 peer-reviewed manuscripts.

Affiliations and expertise

Professor of Orthopedic Surgery, Harvard Medical School; Director, Center for Advanced Orthopedic Studies at Beth Israel Deaconess Medical Center, Boston, MA, United States

Felicia Cosman

Felicia Cosman is Professor of Medicine at Columbia University College of Physicians and Surgeons and Co-Editor in Chief of Osteoporosis International. Dr. Cosman was funded by the NIH through a Specialized Center of Research Program and subsequent individual NIH awards for 30 years and has had grants from the Department of Defense, industry and several foundations and societies. She has published over 170 peer-reviewed papers and over 50 book chapters. In her early research, she utilized dynamic tests of the PTH/Vitamin D axis to investigate effects of menopause, estrogen, and selective estrogen receptor agonists and also to study racial differences in skeletal metabolism. She studied interrelationships among MS, vitamin D deficiency and glucocorticoids, and evaluated causes of stress fractures and peak bone mass accrual in military cadets attending USMA. She also studied vertebral fracture prevalence in the US using dual x-ray based vertebral fracture assessment in an NHANES population. Throughout her career, she has investigated many pharmaceutical agents, including a series of studies on the efficacy and safety of zoledronic acid and the duration and potency of its effects after discontinuation. The main focus of her research has been in the clinical use of anabolic medications for osteoporosis treatment. She has studied teriparatide action using biochemical markers of bone turnover, bone density, central and peripheral computed tomography and finite element analysis as well transiliac crest bone biopsy. In a novel trial, she evaluated the early effect of teriparatide on the rate and location of bone formation in the human femoral neck in patients undergoing total hip replacement for arthritis. She has investigated cyclic, combination and sequential regimens of terriparatide and antiresorptive agents, including alendronate, raloxifene, zoledronic acid and denosumab. She has been a participant in studies evaluating novel PTH formulations and delivery systems and experimental anabolic agents. She was a lead investigator on pivotal studies of abaloparatide and romosozumab and evaluations of the influence of early bone density gains on the persistent effect against fracture. Dr. Cosman is known for advocating early use of anabolic agents in high-risk patients, optimizing treatment sequences, rotating therapies in long-term treatment strategies and considering therapeutic goals for osteoporosis management. She has been a participant on multiple ASBMR task forces and NIH workshops, and many other advisory committees. She was NOF’s Clinical Director for 20 years and lead author of the NOF Clinician’s Guide in 2014. She has been the Co-Editor-in-Chief of Osteoporosis International since 2015 and has received multiple awards including the NOF Generations Award and the ACE Distinction in Endocrinology Award. In 2020, she was given the ASBMR 2020 Frederic C. Bartter Award for excellence in clinical research.

Affiliations and expertise

Professor of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, United States